OptiScan Stock

optiscancorp.comHealthcare / Other HealthcareFounded: 1900Funding to Date: $207.05MM

Optiscan Biomedical is the developer of a monitoring platform for use in hospital intensive care units (ICUs) to support clinicians in detecting changes more rapidly in critically ill patients, enabling more timely intervention.

Register for Details

For more details on financing and valuation for OptiScan, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for OptiScan.

Register Today

Team

Management Team

Carlo Mata
Director of Marketing
Patrick Nugent
Chief Financial Officer
Cary Vance
Chief Executive Officer, President & Board Member
Jim Causey
Vice President, Research & Development

Board Members

Paul Mieyal Ph.D
Wexford Capital
Phillip Stern
Chartline Capital Partners
Kenneth Abramowitz
NGN Capital
Aditya Puri
Xeraya Capital
Charles Liamos
MedVenture Associates

Other companies like OptiScan in the Other Healthcare sector

Sector
Last Round Est. Valuation
$165MM
Sector
Last Round Est. Valuation
$368.08MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$125MM
Sector
Last Round Est. Valuation
$140MM
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$173.59MM
Sector
Last Round Est. Valuation
$300.91MM

News Highlights

OptiScan Biomedical Announces Peer-Reviewed Publications Highlighting First-of-its-Kind Continuous Monitoring Platform for Intensive Care Units | BioSpace
OptiScan Biomedical Announces Peer-Reviewed Publications Highlighting First-of-its-Kind Continuous Monitoring Platform for Intensive Care Units - read this article along with other careers information, tips and advice on BioSpace
OptiScan Biomedical Completes $20M Series E Financing | FinSMEs
OptiScan Biomedical, a developer of an innovative continuous monitoring system for use in the surgical intensive care unit, closed $20m Series E financing
OptiScan raises $20m for bedside glucose monitoring system
OptiScan Biomedical said today that it closed a $20 million Series E round to support the commercialization of its continuous monitoring system, the OptiScanner 5000, in the U.S. The company’s device is an automated bedside blood glucose monitor designed for use in the intensive care unit. The system can measure glucose values from a micro-sample of […]
Updated on: Sep 26, 2023